NeoImmuneTech, Inc. Logo

NeoImmuneTech, Inc.

Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.

950220 | KO

Overview

Corporate Details

ISIN(s):
KR8840140006
LEI:
Country:
United States of America
Address:
2400 Research Boulevard, Suite 250, Rockville, MD 20850, Rockville
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biotechnology company dedicated to developing novel immuno-therapeutics. Founded in 2014, the company's core technology is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 designed to amplify the quantity and enhance the functionality of T cells. This proprietary asset is being developed to treat various cancers and infectious diseases. NeoImmuneTech's research and development efforts focus on exploring NT-I7 as both a monotherapy and in combination with other treatments, aiming to expand the horizons of immuno-oncology and address unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-09-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 94.2 KB
2025-09-16 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (주주배정 후 실권주 일반공모)
Korean 7.8 KB
2025-09-16 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 90.0 KB
2025-09-15 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
Korean 11.0 KB
2025-09-10 00:00
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
Korean 9.6 KB
2025-09-04 00:00
Share Issue/Capital Change
유상증자최종발행가액확정 (주주배정후 실권주 일반공모)
Korean 11.3 KB
2025-09-04 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 38.3 KB
2025-09-04 00:00
Registration Form
[발행조건확정]증권신고서(증권예탁증권)
Korean 218.3 KB
2025-09-04 00:00
Prospectus
[기재정정]투자설명서
Korean 2.7 MB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-20 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-08-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 99.8 KB

Automate Your Workflow. Get a real-time feed of all NeoImmuneTech, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NeoImmuneTech, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NeoImmuneTech, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM

Talk to a Data Expert

Have a question? We'll get back to you promptly.